| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8d595ec481a2a081fed4aa2fd4ff52d8 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2810-859
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10343 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K41-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-45 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-861
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-45
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K41-00 |
| filingDate |
2002-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1698c878733f20dee6c0e5a4ced22ae4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e496f7832261e1ed22c9214096b50492
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_614ee6d4f9387da6033ab768173ddbfc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9a681df41cd5ce638b657c545865e7d8 |
| publicationDate |
2003-08-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2003148984-A1 |
| titleOfInvention |
Molecular chemotherapy enhancement of radiotherapy |
| abstract |
The present invention provides a new approach for cancer treatment by utilizing gene therapy combined with radiation therapy to enhance cytotoxicity in malignant cells. Specifically, the present invention demonstrates that molecular chemotherapy with the cytosine deaminase gene and 5-fluorocytosine is an effective radiosensitizing strategy which may lead to substantial improvement in tumor control, with less normal tissue toxicity than conventional systemic administration of 5-fluorouracil, that would translate into improved cure rates and better survival. A noninvasive method is described for continuous in vivo monitoring of 5-fluorouracil production via magnetic resonance spectroscopy An adenovirus encoding cytosine deaminase gene which selectively replicates in tumor cells with a defective p53 pathway was constructed. Also provided is an adenovirus which encodes a fusion protein of cytosine deaminase and uracil phosphoribosyltransferase. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007036233-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009028842-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007036233-A3 |
| priorityDate |
1998-09-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |